Drug-related problems, adverse drug reactions, and drug–drug interactions as a result of a pandemic that took us by surprise: COVID-19 in Mexico
Abstract
The health emergency caused by the COVID-19 pandemic led to the off-label use of drugs in an improvised manner in the early years, increasing the risk of drug-related problems (DRPs), adverse drug reactions (ADRs), and drug interactions (DDIs) in hospitalized patients. The aim of this study was to evaluate the frequency and characteristics of DRPs, ADRs, and DDIs in patients hospitalized for COVID-19 in a private hospital in Mexico.
An observational, descriptive, and cross-sectional study was conducted using data from 280 patients hospitalized with COVID-19 at the Star Médica Tlalnepantla Hospital in 2021. DRPs, ADRs, and DDIs were identified and analysed by reviewing clinical records and the hospital’s Pharmacy Department databases.
We observed 45.36% of patients presented at least one DRP, among which prescription errors were the most frequent. A total of 17 ADRs were identified, mainly associated with dexamethasone and levofloxacin. Nearly 87% of patients presented at least one DDI, in which glucocorticoids were the most frequently involved group of drugs. Age and the number of comorbidities were significantly associated with the occurrence of DRPs and DDIs.
The pharmacotherapeutic decisions taken during the COVID-19 pandemic contributed to the occurrence of DRPs and DDIs. However, it is important to recognize the complexity of the early stages of the pandemic, when there was high pressure on the health system and limited clinical evidence. Strengthening the role of…
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.